Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

Researchers at the University of Arizona have identified oats as a food that may have effects similar to those of a ...

IRAKLIA, the first phase 3 multiple myeloma study to use an on-body injector, finds the same efficacy and pharmacokinetics in ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Scientific research has gifted us with a range of evidence-based options to protect ourselves from getting infected with HIV ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

Fremanezumab vs placebo significantly reduced monthly migraine days and depressive symptoms in patients with migraine and comorbid major depressive disorder.